covid
Buscar en
Infectio
Toda la web
Inicio Infectio Status of dhps and dhfr genes of Plasmodium falciparum in Colombia before artemi...
Información de la revista
Vol. 16. Núm. 1.
Páginas 37-44 (marzo 2012)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 16. Núm. 1.
Páginas 37-44 (marzo 2012)
Open Access
Status of dhps and dhfr genes of Plasmodium falciparum in Colombia before artemisinin based treatment policy
Estado de los genes dhps y dhfr de Plasmodium falciparum en Colombia antes de la recomendación de tratamiento basado en artemisinina
Visitas
1968
Andrés Villa1,, Jaime Carmona-Fonseca1, Agustín Benito2, Alonso Martínez3, Amanda Maestre1,
Autor para correspondencia
emaestre@gmail.com

Correspondencia: Carrera 51 D Nº 62-29, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia. teléfono: (574) 219-6025; fax: (574) 219-6051.
1 Grupo Salud y Comunidad, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
Dirección actual: Escuela de Microbiología, Universidad de Antioquia, Medellín, Colombia
2 Centro Nacional de Medicina Tropical, Instituto de Salud Carlos III, Madrid, Spain
3 Grupo Bacterias y Cáncer, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Abstract
Introduction

Surveillance of the genetic characteristics of dhps and dhfr can be useful to outline guidelines for application of intermittent preventive therapy in Northwest Colombia and to define the future use of antifolates in artemisinin-based combination therapy schemes.

Objective

To evaluate the frequency of mutations in dhps and dhfr and to characterize parasite populations using msp-1, msp-2 and glurp in historic samples before artemisinin-based therapy was implemented in the country.

Methods

A controlled clinical study was carried out on randomly selected Plasmodium falciparum infected volunteers of Northwest Colombia (Turbo and Zaragoza). A sample size of 25 subjects per region was calculated. Treatment efficacy to antifolates was assessed. Molecular analyses included P. falciparum genotypes by msp-1, msp-2 and glurp and evaluation of the status of codons 16, 51, 59, 108 and 164 of dhfr and 436, 437, 540, 581 and 613 of dhps.

Results

In total 78 subjects were recruited. A maximum number of 4 genotypes were detected by msp-1, msp-2 and glurp. Codons 16, 59 and 164 of the dhfr gene exhibited the wild-type form, while codons 51 and 108 were mutant. In the dhps gene, the mutant 437 glycine was detected in 85% on day 0, while codons 436, 540, 581 and 613 were wild-type.

Conclusions

Plasmodium falciparum populations were very homogeneous in this region of Colombia, and the triple mutants of dhfr and dhps Asn108, Ile51 and Gly437 were predominant in clinical isolates.

Keywords:
Plasmodium falciparum
malaria
dhps
dhfr
resistance
sulphadoxine
Colombia
Resumen
Introducción

La vigilancia de las características genéticas de dhps y dhfr puede utilizarse para delinear guías de aplicación de terapia preventiva intermitente en el nordeste de Colombia y para definir el uso futuro de los antifolatos en esquemas terapéuticos basados en artemisinina.

Objetivo

Evaluar la frecuencia de mutaciones en dhps y dhfr, y caracterizar las poblaciones parasitarias usando msp-1, msp-2 y glurp, en muestras históricas obtenidas antes de la implementación en el país de la terapia basada en artemisinina.

Métodos

Se llevó a cabo un estudio clínico controlado en voluntarios infectados con Plasmodium falciparum seleccionados aleatoriamente y provenientes del nordeste de Colombia (Turbo y Zaragoza). Se calculó una muestra de 25 sujetos por región. Se evaluó la eficacia al tratamiento con antifolatos. Los análisis moleculares incluyeron la obtención de genotipos de msp-1, msp-2 y glurp y el estado de los codones 16, 51, 59, 108 y 164 de dhfr, y 436, 437, 5540, 581 y 613 de dhps.

Resultados

Se estudiaron 78 sujetos. Se detectó un número máximo de 4 genotipos con msp-1, msp-2 y glurp. Los codones 16, 59 y 164 del gen dhfr se encontraron en su forma silvestre, mientras que los codones 51 y 108 estaban mutados. En el gen dhps, la forma mutante (glicina) en el codón 437, se detectó en 85% el día 0, mientras que los codones 436, 540, 581 y 613 se encontraron silvestres.

Conclusiones

Las poblaciones de P. falciparum son muy homogéneas en esta región de Colombia y las triple mutantes de dhfr y dhps Asn108, Ile51 and Gly437, predominaron en los aislamientos clínicos.

Palabras clave:
Plasmodium falciparum
malaria
dhps
dhfr
resistencia
sulfadoxina
Colombia
El Texto completo está disponible en PDF
References
[1.]
S. Blair-Trujillo, L. Lacharme-Lora, J. Carmona-Fonseca.
Resistance of Plasmodium falciparum to antimalarial drugs in Zaragoza (Antioquia, Colombia), 1998.
Mem Inst Oswaldo Cruz, 97 (2002), pp. 401-406
[2.]
J. Carmona-Fonseca, A. Tobón, G. Álvarez, S. Blair.
El tratamiento amodiaquina-sulfadoxina-pirimetamina tiene eficacia del 98% para la malaria falciparum no complicada (Antioquia, Colombia; 2003.
Iatreia, 18 (2005), pp. 5-26
[3.]
J. Carmona-Fonseca, E. Arango, S. Blair.
Gametocitemia en malaria por Plasmodium falciparum tratada con amodiaquina o artesunato.
Biomedica, 28 (2008), pp. 195-212
[4.]
F. Méndez, A. Muñoz, G. Carrasquilla, D. Jurado, M. Arévalo-Herrera, J.F. Cortese, et al.
Determinants of treatment response to sulfadoxine- pyrimethamine and subsequent transmission potential in falciparum malaria.
Am J Epidemiol, 156 (2002), pp. 230-238
[5.]
S. Blair, J. Carmona-Fonseca, J.G. Piñeros, A. Ríos, T. Álvarez, G. Álvarez, et al.
Therapeutic efficacy test in malaria falciparum in Antioquia Colombia.
[6.]
J.A. Galindo, F.A. Cristiano, A. Knudson, R.S. Nicholls, A.P. Guerra.
Mutaciones puntuales en los genes dhfr y dhps de Plasmodium falciparum de tres regiones endémicas para malaria en Colombia.
Biomedica., 30 (2010), pp. 56-64
[7.]
L.E. Giraldo, M.C. Acosta, L.A. Labrada, A. Praba, S. Montenegro-James, N.G. Saravia, et al.
Frequency of the Asn-108 and Thr-108 point mutations in the dihydrofolate reductase gene in Plasmodium falciparum from southwest Colombia.
Am J Trop Med Hyg., 59 (1998), pp. 124-128
[8.]
D. Gómez, J. Chaparro, C. Rubiano, M.O. Rojas, M. Wasserman.
Genetic diversity of Plasmodium falciparum field samples from an isolated Colombian village.
Am J Trop Med Hyg., 67 (2002), pp. 611-616
[9.]
A.P. Guerra, A. Knudson, R.S. Nicholls, J.A. Galindo, Z. Ravid, S. Rahirant, et al.
Genotipificación de los genes msp1 (bloque 2) y dhfr (codón108) de Plasmodium falciparum en muestras de campo recolectadas en cuatro localidades endémicas de Colombia.
Biomedica., 26 (2006), pp. 101-112
[10.]
N.I. Rallon, L.E. Osorio, L.E. Giraldo.
Lack of an association between the ASN-108 mutation in the dihydrofolate reductase gene and in vivo resistance to sulfadoxine/pyrimethamine in Plasmodium falciparum.
Am J Trop Med Hyg., 61 (1999), pp. 245-248
[11.]
N. Schmider, G. Peyerl-Hoffmann, M. Restrepo, T. Jelinek.
Short communication: point mutations in the dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum isolates from Colombia.
Trop Med Int Health., 8 (2003), pp. 129-132
[12.]
H.A. Babiker, I.M. Hastings, G. Swedberg.
Impaired fitness of drugresistant malaria parasites: evidence and implication on drug-deployment policies.
Expert Rev Anti Infect Ther., 7 (2009), pp. 581-593
[13.]
M. Chavchich, L. Gerena, J. Peters, N. Chen, Q. Cheng, D.E. Kyle.
Role of pfmdr1 amplification and expression in induction of resistance to artemisinin derivatives in Plasmodium falciparum.
Antimicrob Agents Chemother., 54 (2010), pp. 2455-2464
[14.]
G. Hutton, D. Schellenberg, F. Tediosi, E. Macete, E. Kahigwa, B. Sigauque, et al.
Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania.
Bull World Health Organ., 87 (2009), pp. 123-129
[15.]
E.R. Lozovsky, T. Chookajorn, K.M. Brown, M. Imwong, P.J. Shaw, S. Kamchonwongpaisan, et al.
Stepwise acquisition of pyrimethamine resistance in the malaria parasite.
Proc Natl Acad Sci U.S.A, 106 (2009), pp. 12025-12030
[16.]
D.S. Peterson, D. Walliker, T.E. Wellems.
Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria.
Proc Natl Acad Sci U.S.A., 85 (1988), pp. 9114-9118
[17.]
C.V. Plowe, J.F. Cortese, A. Djimde, O.C. Nwanyanwu, W.M. Watkins, P.A. Winstanley, et al.
Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance.
J Infect Dis., 176 (1997), pp. 1590-1596
[18.]
T. Triglia, J.G. Menting, C. Wilson, A.F. Cowman.
Mutations in dihydropteroate synthase are responsible for sulfone sulfonamide resistance in Plasmodium falciparum.
Proc Natl Acad Sci U.S.A, 94 (1997), pp. 13944-13949
[19.]
P. Wang, D.R. Brooks, P.F. Sims, J.E. Hyde.
A mutation-specific PCR system to detect sequence variation in the dihydropteroate synthetase gene of Plasmodium falciparum.
Mol Biochem Parasitol., 71 (1995), pp. 115-125
[20.]
J. Carmona-Fonseca.
La malaria en Colombia, Antioquia y las zonas de Urabá y Bajo Cauca: panorama para interpretar la falla terapéutica antimalárica Parte 1.
Iatreia, 16 (2003), pp. 299-318
[21.]
J. Carmona-Fonseca.
La malaria en Colombia, Antioquia y las zonas de Urabá y Bajo Cauca: panorama para interpretar la falla terapéutica antimalárica Parte 2.
Iatreia, 17 (2004), pp. 34-53
[22.]
G. Snounou, B. Singh, Nested PCR.
analysis of Plasmodium parasites.
Methods Mol Med., 72 (2002), pp. 189-203
[23.]
J.M. Rubio, A. Benito, P.J. Berzosa, J. Roche, S. Puente, M. Subirats, et al.
Usefulness of seminested multiplex PCR in surveillance of imported malaria in Spain.
J Clin Microbiol., 37 (1999), pp. 3260-3264
[24.]
M.L. Sierra, L.M. Vélez, A.M. Castañeda, L.A. Galeano, A.L. Molina, Z. Tabares.
. Diagnóstico de la situación de Salud en Antioquia.
Revista Epidemiológica de Antioquia, 25 (2000), pp. 129-132
[25.]
L.K. Basco, R. Tahar, P. Ringwald.
Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites.
Antimicrob Agents Chemother., 42 (1998), pp. 1811-1814
[26.]
OMS-OPS.
Evaluación de la eficacia terapéutica de los medicamentos para el tratamiento del paludismo por Plasmodium falciparum sin complicaciones en las Américas.
WHO, (1998),
[27.]
K.C. Kain, D.E. Lanar.
Determination of genetic variation within Plasmodium falciparum by using enzymatically amplified DNA from filter paper disks impregnated with whole blood.
J Clin Microbiol., 29 (1991), pp. 1171-1174
[28.]
G. Snounou, S. Viriyakosol, X.P. Zhu, W. Jarra, L. Pinheiro, V.E. do Rosario, et al.
High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction.
Mol Biochem Parasitol., 61 (1993), pp. 315-320
[29.]
G. Snounou, X. Zhu, N. Siripoon, W. Jarra, S. Thaithong, K.N. Brown, et al.
Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand.
Trans R Soc Trop Med Hyg., 93 (1999), pp. 369-374
[30.]
M.T. Duraisingh, J. Curtis, D.C. Warhurst.
Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion.
Exp Parasitol., 89 (1998), pp. 1-8
[31.]
C.V. Plowe, A. Djimde, M. Bouare, O. Doumbo, T.E. Wellems.
Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa.
Am J Trop Med Hyg., 52 (1995), pp. 565-568
[32.]
O.K. Doumbo, K. Kayentao, A. Djimde, J.F. Cortese, Y. Diourte, A. Konaré, et al.
Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis.
J Infect Dis., 182 (2000), pp. 993-996
[33.]
A.A. Djimde, O.K. Doumbo, O. Traore, A.B. Guindo, K. Kayentao, Y. Diourte, et al.
Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria.
Am J Trop Med Hyg., 69 (2003), pp. 558-563
[34.]
L. Montoya, A. Maestre, J. Carmona, D. Lopes, V. Do Rosario, S. Blair.
Plasmodium falciparum: diversity studies of isolates from two Colombian regions with different endemicity.
Exp Parasitol., 104 (2003), pp. 14-19
[35.]
A.A. Eskandarian, H. Keshavarz, L.K. Basco, F. Mahboudi.
Do mutations in Plasmodium falciparum dihydropteroate synthase and dihydrofolate reductase confer resistance to sulfadoxine-pyrimethamine in Iran?.
Trans R Soc Trop Med Hyg., 96 (2002), pp. 96-98
[36.]
M.L. Gatton, L.B. Martin, Q. Cheng.
Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum.
Antimicrob Agents Chemother., 48 (2004), pp. 2116-2123
[37.]
T. Jelinek, A.H. Kilian, G. Kabagambe, F. von Sonnenburg.
Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in Uganda: correlation with polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes.
Am J Trop Med Hyg., 61 (1999), pp. 463-466
[38.]
H.S. Nagesha, S. Din, G.J. Casey, A.I. Susanti, D.J. Fryauff, J.C. Reeder, et al.
Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in-vivo drug resistance in West Papua, Indonesia.
Trans R Soc Trop Med Hyg., 95 (2001), pp. 43-49
[39.]
J. Carmona-Fonseca.
Nuevos tratamientos para el paludismo en Colombia, 2006.
Acta Medica Colombiana., 32 (2007), pp. 157-163
[40.]
J. Carmona-Fonseca.
¿Nuevos tratamientos para el paludismo en Colombia, 2007?.
Acta Medica Colombiana, 32 (2007), pp. 246-248
[41.]
S. Biswas.
Associations of antifolate resistance in vitro and point mutations in dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum.
J Postgrad Med., 50 (2004), pp. 17-20
[42.]
A.M. Nzila, E.K. Mberu, J. Sulo, H. Dayo, P.A. Winstanley, C.H. Sibley, et al.
Towards an understanding of the mechanism of pyrimethaminesulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites.
Antimicrob Agents Chemother., 44 (2000), pp. 991-996
[43.]
C.H. Sibley, J.E. Hyde, P.F. Sims, C.V. Plowe, J.G. Kublin, E.K. Mberu, et al.
Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?.
Trends Parasitol., 17 (2001), pp. 582-588
[44.]
L.K. Basco, R. Tahar, A. Keundjian, P. Ringwald.
Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria.
J Infect Dis., 182 (2000), pp. 624-628
[45.]
S.A. Omar, I.S. Adagu, D.C. Warhurst.
Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?.
Trans R Soc Trop Med Hyg., 95 (2001), pp. 315-319
Copyright © 2012. Asociación Colombiana de Infectología (ACIN)
Descargar PDF
Opciones de artículo